AN ANIMAL-MODEL OF FOCAL, SUBACUTE, VIRAL RETINITIS

被引：13

作者：

FREEMAN, WR

SCHNEIDERMAN, TE

WILEY, CA

LISTHAUS, AD

SVENDSEN, P

MUNGUIA, D

BERGERONLYNN, G

机构：

[1] Departments of Ophthalmology, San Diego, CA

[2] Departments of Pathology, University of California, San Diego, CA

[3] Departments of Neurosciences, University of California, San Diego, CA

来源：

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES | 1993年 / 13卷 / 03期

关键词：

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL DRUGS; CYTOMEGALOVIRUS; HERPES; VIRAL RETINITIS;

D O I：

10.1097/00006982-199313030-00005

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

To study local intravitreal therapies for retinitis due to herpes viruses, an animal model of focal, subacute, relatively nonlethal herpes family retinitis is needed. Herpes simplex virus type 1 (HSV-1) was injected into the subretinal space of 33 Dutch pigmented rabbit eyes. The animals were observed for up to 42 days after the inoculation. All inoculated eyes developed a focal, enlarging area of retinitis in a predictable manner, showing focal enlarging areas of retinal opacification and necrosis with variable retinal hemorrhage. In the inoculated eyes, retinal detachment developed in all animals within 21 days; 33% of the animals developed focal retinitis in the uninoculated eye. Histologic examination showed encephalitis to be present in 11 (73%) of the 15 animals studied after 1 week. This model may be used to evaluate the therapeutic efficacy of new antiviral agents and modalities in the treatment of herpes family viral retinitis. The model is most similar to herpes simplex or zoster retinitis in humans, but also shares some similarities (and differences) with cytomegalovirus (CMV) retinitis in humans.

引用

页码：214 / 221

页数：8

共 32 条

[1]

Freeman W.R., Lerner C.W., Mines J.A., Et al., A prospective study of the ophthalmologic findings in the acquired immune deficiency syndrome, Am J Ophthalmol, 97, pp. 133-142, (1984)

[2]

Holland G.N., Pepose J.S., Pettit T.H., Et al., Acquired immune deficiency syndrome: Ocular manifestations, Ophthalmology, 90, pp. 859-873, (1983)

[3]

Newman N.M., Mandel M.R., Gullett J., Fujikawa L., Clinical and histologic findings in opportunistic ocular infections: Part of a new syndrome of acquired immunodeficiency, Arch Phthalmol, 101, pp. 396-401, (1983)

[4]

Palestine A.G., Stevens G., Lane H.C., Et al., Treatment of cytomegalovirus retinitis with dihydroxy propoxymethyl guanine, Am J Ophthalmol, 101, pp. 95-101, (1986)

[5]

Henderly D.E., Freeman W.R., Causey D.M., Rao N.A., Cytomegalovirus retinitis and response to therapy with ganciclovir, Ophthalmology, 94, pp. 425-434, (1987)

[6]

Fanning M.M., Read S.E., Benson M., Et al., Foscarnet therapy of cytomegalovirus retinitis in aids, J Acquired Immune Deficiency Syndromes, 3, 5, pp. 472-479, (1990)

[7]

Freeman W.R., Intraocular antiviral therapy, Arch Ophthalmol, 107, pp. 1737-1739, (1989)

[8]

Matthews T., Boehme R., Antiviral activity and mechanism of action of ganciclovir, Rev Infect Dis, 10, pp. 490-494, (1990)

[9]

Maurice D.M., Use of intravitreal ganciclovir (Propoxymethyl guanine) for cytomegalovirus retinitis in a patient with aids, Am J Ophthalmol, 103, pp. 842-844, (1987)

[10]

Ussery F.M., Gibson S.R., Conklin R.H., Et al., Intravitreal ganciclovir in the treatment of aids-associated cytomegalovirus retinitis, Ophthalmology, 95, pp. 640-648, (1988)

← 1 2 3 4 →